TY - CHAP
T1 - Pre-clinical and Clinical Management of Osteochondral Lesions
AU - Pina, Sandra
AU - Ribeiro, Viviana
AU - Oliveira, Joaquim Miguel
AU - Reis, Rui Luís
N1 - Funding Information:
The research leading to this work has received funding from the European Union’s Seventh Framework Program (FP7/2007-2013) under Grant Agreement No REGPOT-CT2012-316331-POLARIS, and from QREN (ON.2—NORTE-01-0124-FEDER-000016) cofinanced by North Portugal Regional Operational Program (ON.2—O Novo Norte), under the National Strategic Reference Framework (NSRF), through the European Regional Development Fund (ERDF). Thanks are also due to the Portuguese Foundation for Science and Technology (FCT) and FSE/POCH (Fundo Social Europeu através do Programa Operacional do Capital Humano), PD/59/2013, for the project PEst-C/SAU/LA0026/201, for the fellowship grants of Sandra Pina (SFRH/BPD/108763/2015) and Viviana Ribeiro (PD/BD/113806/2015), and for the distinction attributed to J.M. Oliveira under the Investigator FCT program (IF/00423/2012).
Publisher Copyright:
© 2017, Springer International Publishing AG.
PY - 2017
Y1 - 2017
N2 - The majority of osteochondral (OC) lesions occur after injury or trauma of both bone and the overlying cartilage, and symptoms are pain and disability, leading to the risk of inducing osteoarthritis. These lesions are currently repaired by non-surgical and surgical methods or by advanced tissue engineering strategies, which require a proof of efficacy and safety for regulatory approval for human application. Pre-clinical studies using animal models have been the support of OC repair and regeneration with successful clinical outcomes. Small animal models as mice and rabbits, and large animal models as sheep, goats and horses, have been most commonly used according with the outcome goals. Small animals are recommended as a proof of concept, while large animals are endorsed for truly translational research in order to get the regulatory approval for clinical use in humans. An up-to-date of the in vivo studies using different animal models and ongoing clinical trials for the repair and regeneration of OC lesions are presented. Commercialised products for OC repair are also indicated.
AB - The majority of osteochondral (OC) lesions occur after injury or trauma of both bone and the overlying cartilage, and symptoms are pain and disability, leading to the risk of inducing osteoarthritis. These lesions are currently repaired by non-surgical and surgical methods or by advanced tissue engineering strategies, which require a proof of efficacy and safety for regulatory approval for human application. Pre-clinical studies using animal models have been the support of OC repair and regeneration with successful clinical outcomes. Small animal models as mice and rabbits, and large animal models as sheep, goats and horses, have been most commonly used according with the outcome goals. Small animals are recommended as a proof of concept, while large animals are endorsed for truly translational research in order to get the regulatory approval for clinical use in humans. An up-to-date of the in vivo studies using different animal models and ongoing clinical trials for the repair and regeneration of OC lesions are presented. Commercialised products for OC repair are also indicated.
KW - Articular Cartilage
KW - Articular Cartilage Defect
KW - Autologous Chondrocytes Implantation
KW - Hyaline Cartilage
KW - Subchondral Bone
UR - http://www.scopus.com/inward/record.url?scp=85039758603&partnerID=8YFLogxK
U2 - 10.1007/978-3-319-44785-8_8
DO - 10.1007/978-3-319-44785-8_8
M3 - Chapter
AN - SCOPUS:85039758603
T3 - Studies in Mechanobiology, Tissue Engineering and Biomaterials
SP - 147
EP - 161
BT - Studies in Mechanobiology, Tissue Engineering and Biomaterials
PB - Springer
ER -